ReviewHematology/oncology clinics of North America2011
New insights into the biology of renal cell carcinoma.
Review in Hematology/oncology clinics of North America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Metabolism of kidney cancer: from the lab to clinical practice.European urology · 2013Pooled it
- The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Trial
- Surgical resection of a solid posterior cranial fossa hemangioblastoma causing obstructive hydrocephalus in a pediatric patient.Surgical neurology international · 2026Article
- Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis.Current oncology reports · 2024Review
- Radiogenomics and Texture Analysis to Detect von Hippel-Lindau (VHL) Mutation in Clear Cell Renal Cell Carcinoma.Current issues in molecular biology · 2024Review
- Lipid metabolism reprogramming in renal cell carcinoma.Cancer metastasis reviews · 2022Review
- Review
- Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma.Frontiers in immunology · 2021Review
- The immunology of renal cell carcinoma.Nature reviews. Nephrology · 2020Review
- What morphology can teach us about renal cell carcinoma clonal evolution.Kidney cancer journal : official journal of the Kidney Cancer Association · 2020Article
- The mProceedings of the National Academy of Sciences of the United States of America · 2020Article
- Leveraging insights into cancer metabolism-a symposium report.Annals of the New York Academy of Sciences · 2020Review
- S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma.Cancer research · 2019Article
- Hypoxia-inducible factor (HIF)-prolyl hydroxylase 3 (PHD3) maintains highThe Journal of biological chemistry · 2019Article
- A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma.Bioscience reports · 2017Article
- RNF20 Suppresses Tumorigenesis by Inhibiting the SREBP1c-PTTG1 Axis in Kidney Cancer.Molecular and cellular biology · 2017Article
- Interaction between von Hippel-Lindau Protein and Fatty Acid Synthase Modulates Hypoxia Target Gene Expression.Scientific reports · 2017Article
- HIF prolyl hydroxylase PHD3 regulates translational machinery and glucose metabolism in clear cell renal cell carcinoma.Cancer & metabolism · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Ninety percent or more of kidney cancers are believed to be of epithelial cell origin, and are referred to as renal cell carcinoma (RCC), which are further subdivided based on histology into clear-cell RCC (75%), papillary RCC (15%), chromophobe tumor (5%), and oncocytoma (5%). Some genes confer an increased risk of these various histologic RCC subtypes. In practice, there is some overlap among the histologic subtypes, and there are some shared molecular features among these tumor types. This review focuses primarily on the most common form of RCC, clear-cell renal carcinoma, noting some recent advances in the other histologic subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.